These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study. Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071 [TBL] [Abstract][Full Text] [Related]
3. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil. Risinger R; Hard M; Weiden PJ Psychopharmacol Bull; 2017 Aug; 47(3):26-34. PubMed ID: 28839337 [TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil. Hard ML; Wehr AY; Sadler BM; Mills RJ; von Moltke L Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):461-469. PubMed ID: 29943125 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. Hard ML; Mills RJ; Sadler BM; Wehr AY; Weiden PJ; von Moltke L CNS Drugs; 2017 Jul; 31(7):617-624. PubMed ID: 28597226 [TBL] [Abstract][Full Text] [Related]
6. Aripiprazole Lauroxil: A Review in Schizophrenia. Frampton JE Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572 [TBL] [Abstract][Full Text] [Related]
7. Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. Hard ML; Mills RJ; Sadler BM; Turncliff RZ; Citrome L J Clin Psychopharmacol; 2017 Jun; 37(3):289-295. PubMed ID: 28350572 [TBL] [Abstract][Full Text] [Related]
8. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Citrome L Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020 [TBL] [Abstract][Full Text] [Related]
9. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Turncliff R; Hard M; Du Y; Risinger R; Ehrich EW Schizophr Res; 2014 Nov; 159(2-3):404-10. PubMed ID: 25266547 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia. Hard ML; Wehr AY; Du Y; Weiden PJ; Walling D; von Moltke L J Clin Psychopharmacol; 2018 Oct; 38(5):435-441. PubMed ID: 30015676 [TBL] [Abstract][Full Text] [Related]
11. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil. Nasrallah HA; Aquila R; Stanford AD; Jamal HH; Weiden PJ; Risinger R Psychopharmacol Bull; 2017 Aug; 47(3):35-43. PubMed ID: 28839338 [TBL] [Abstract][Full Text] [Related]
12. Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults. Samalin L; Boudieu L; Llorca PM Expert Rev Neurother; 2024 Mar; 24(3):291-298. PubMed ID: 38299536 [TBL] [Abstract][Full Text] [Related]
13. Aripiprazole Lauroxil NanoCrystal Ehret MJ; Davis E; Luttrell SE; Clark C Clin Schizophr Relat Psychoses; 2018; 12(2):92-96. PubMed ID: 30040476 [TBL] [Abstract][Full Text] [Related]
14. An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection. Wang Y; Wang X; Harlin M; Larsen F; Panni M; Yildirim M; Madera J; Arias L; Forbes A; Mustafa N; Ruiz-White I; Raoufinia A Curr Med Res Opin; 2021 Nov; 37(11):1961-1972. PubMed ID: 34407720 [TBL] [Abstract][Full Text] [Related]
15. Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia. Jain R; Meyer J; Wehr A; Rege B; von Moltke L; Weiden PJ CNS Spectr; 2020 Jun; 25(3):323-330. PubMed ID: 31111801 [TBL] [Abstract][Full Text] [Related]